SCHEMBL31412569

SCHEMBL31412569

CC(C)(C)OC(=O)N1C[C@H](O)[C@H](c2ccc(Cl)cc2)C1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ RORC P51449 1/20 0.52
▸ MEN1 O00255 3/20 0.49
▸ KMT2A Q03164 3/20 0.49
▸ MC4R P32245 2/20 0.48
▸ PDE4B Q07343 6/20 0.47
▸ STS P08842 2/20 0.46
▸ NAMPT P43490 1/20 0.42
▸ PSEN1 P49768 1/20 0.41
▸ PSEN2 P49810 1/20 0.41
▸ APH1B Q8WW43 1/20 0.41
▸ NCSTN Q92542 1/20 0.41
▸ APH1A Q96BI3 1/20 0.41
▸ PSENEN Q9NZ42 1/20 0.41
▸ USP2 O75604 1/20 0.41
▸ HPGD P15428 1/20 0.41
▸ NPSR1 Q6W5P4 1/20 0.41
▸ HSD17B10 Q99714 1/20 0.41
▸ KCNK3 O14649 1/20 0.41
▸ KCNK9 Q9NPC2 1/20 0.41
▸ TACR1 P25103 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17514225 1.00 RORC (0.52) RORCMEN1KMT2AMC4RPDE4B
SCHEMBL31412611 1.00 RORC (0.52) RORCMEN1KMT2AMC4RPDE4B
SCHEMBL31341850 0.88 STS (0.51) RORCMEN1KMT2AMC4RPDE4B
SCHEMBL1989607 0.88 SMN1; SMN2 (0.48) RORCMEN1KMT2ANPSR1
SCHEMBL29538387 0.88 SMN1; SMN2 (0.48) RORCMEN1KMT2ANPSR1
SCHEMBL3993928 0.86 RORC (0.55) RORCMEN1KMT2APDE4BNAMPT
SCHEMBL16070094 0.86 RORC (0.55) RORCMEN1KMT2APDE4BNAMPT
SCHEMBL1992736 0.86 RORC (0.52) RORCPDE4BNAMPTKCNK3KCNK9
SCHEMBL6917693 0.86 RORC (0.52) RORCPDE4BNAMPTKCNK3KCNK9
SCHEMBL16032347 0.86 RORC (0.55) RORCMEN1KMT2APDE4BNAMPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025045746-A1 PYRAZOLE DERIVATIVES AS SARM1 INHIBITORS USEFUL FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS F. HOFFMANN-LA ROCHE AG (CH) 2025-03-06 — — WO disclosed
Send feedback